Eli Lilly Unveils Promising Data for New JAK2 Inhibitor in Myelofibrosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Progress: Eli Lilly's AJX-101 study reveals promising safety and clinical activity for its novel type II JAK2 inhibitor AJ1-11095 in myelofibrosis patients who have failed type I JAK2 inhibitors, indicating significant therapeutic potential.
- Efficacy Metrics: Among 23 patients, 70% achieved a 35% reduction in spleen volume and the same percentage reported a 50% improvement in symptom burden at 12 weeks, suggesting the drug's efficacy surpasses existing treatments.
- Safety Assessment: The overall safety profile of AJ1-11095 is favorable, with no dose-limiting toxicities observed and 78% of patients remaining in the study during the dose escalation phase, indicating good tolerability and persistence.
- Future Research Directions: Lilly plans to further evaluate AJ1-11095 in high-risk polycythemia vera patients and those with myelofibrosis who have not yet received a JAK2 inhibitor, aiming to expand its clinical application and improve patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1160.950
Low
950.00
Averages
1192
High
1500
Current: 1160.950
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Unveils Promising Data for New JAK2 Inhibitor in Myelofibrosis
- Clinical Trial Progress: Eli Lilly's AJX-101 study reveals promising safety and clinical activity for its novel type II JAK2 inhibitor AJ1-11095 in myelofibrosis patients who have failed type I JAK2 inhibitors, indicating significant therapeutic potential.
- Efficacy Metrics: Among 23 patients, 70% achieved a 35% reduction in spleen volume and the same percentage reported a 50% improvement in symptom burden at 12 weeks, suggesting the drug's efficacy surpasses existing treatments.
- Safety Assessment: The overall safety profile of AJ1-11095 is favorable, with no dose-limiting toxicities observed and 78% of patients remaining in the study during the dose escalation phase, indicating good tolerability and persistence.
- Future Research Directions: Lilly plans to further evaluate AJ1-11095 in high-risk polycythemia vera patients and those with myelofibrosis who have not yet received a JAK2 inhibitor, aiming to expand its clinical application and improve patient outcomes.
See More
Eli Lilly Unveils Promising Data for New JAK2 Inhibitor AJ1-11095
- Clinical Trial Progress: Eli Lilly's AJX-101 study evaluated the first-in-class type II JAK2 inhibitor AJ1-11095 in 23 patients with myelofibrosis previously treated with type I JAK2 inhibitors, demonstrating a promising safety profile and potential new treatment options for resistant patients.
- Significant Efficacy Metrics: The study found that 70% of patients achieved at least a 35% reduction in spleen volume (SVR35) and 70% experienced over 50% symptom improvement (TSS50) at week 12, indicating AJ1-11095's potential to enhance patient quality of life.
- Variant Frequency Reduction: Among the 23 patients, 21 showed a decrease in driver mutation variant allele frequency (VAF), with 59% of patients achieving a VAF reduction of 20% or more and 35% achieving a reduction of 50% or more at week 24, highlighting AJ1-11095's unique advantage in tumor progression suppression.
- Manageable Safety Profile: The overall safety of AJ1-11095 was manageable with no dose-limiting toxicities observed, and 78% of patients remain in the study, with common adverse events including anemia and dysgeusia, demonstrating the drug's feasibility in clinical applications.
See More
Future Outlook for Obesity Drugs Market
- Intensifying Market Competition: At the conference in New Orleans, Eli Lilly and Novo Nordisk showcased their GLP-1 drugs, with Novo's Wegovy prescriptions exceeding 3 million within five months of launch, indicating that oral medications are attracting more consumers and could reshape the weight loss drug market.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data, and if their GLP-1 drugs succeed in Phase 3 trials, they are expected to hit the market by 2029, further enriching market options and intensifying competition.
- Innovative Administration Methods: Pfizer's new drug shows potential for monthly administration, which could be more convenient than current weekly injections, while Amgen is testing a drug that could be administered monthly or quarterly, aiming to enhance patient adherence to treatment.
- Future Market Outlook: With approximately 2.5 billion people globally classified as overweight and 890 million as obese, the competition will intensify as new drugs continue to emerge, while Lilly and Novo are also working to improve insurance coverage for GLP-1 drugs, which is expected to attract more patients.
See More
Pfizer's New Drug Intensifies Competition in Weight Loss Market
- Pfizer's Drug Introduction: Pfizer's weight loss drug berobenatide, requiring only monthly injections, is set to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound, potentially putting market pressure on both companies.
- Clinical Trial Results: The latest phase 2b trial showed an average weight loss of 15.9%, and while Novo Nordisk and Eli Lilly's drugs may perform better under clinical management, the convenience of berobenatide could attract more patients.
- Market Outlook Analysis: Morgan Stanley projects the weight loss drug market will reach $150 billion by 2035, and Pfizer's entry may weaken the pricing power of Novo Nordisk and Eli Lilly, impacting their future revenues.
- Long-term Strategic Impact: Pfizer plans to launch multiple weight loss drugs in the coming years, and although the short-term revenue contribution may be limited, the enhanced competitiveness poses a potential threat to shareholders of Novo Nordisk and Eli Lilly.
See More
Analysis of Three Dividend Growth Stocks
- Eli Lilly's Strong Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase, with EPS soaring 156% to $8.55, driven by the success of its GLP-1 drug Mounjaro, and forecasts 2026 revenue between $82 billion and $85 billion, indicating robust market demand and future growth potential.
- Parker-Hannifin's Resilient Performance: Parker-Hannifin raised its dividend by 11% to $2 per share in April, marking its 70th consecutive year of increases, with a five-year dividend growth rate nearing 94%, while overall revenue grew 11% to $5.5 billion in Q3, showcasing its strong pricing power in global supply chains and clean technology infrastructure.
- Microsoft's Dual Growth in Revenue and Dividends: Microsoft reported Q3 revenue of $82.9 billion, an 18% year-over-year increase, with EPS rising 23% to $4.27, and a 10% dividend increase to $0.91 per quarter last September, reflecting its sustained growth in cloud computing and AI sectors.
- Investment Opportunities in Dividend Growth: These three companies have not only increased dividends by over 50% in the past five years but also maintain payout ratios below 27%, indicating their capacity for continued dividend increases, making them suitable for investors seeking stable income and capital appreciation.
See More
Pfizer Enters Weight Loss Drug Market with Berobenatide
- Drug Development Progress: Pfizer's weight loss drug berobenatide shows promise in its latest phase 2b trial, indicating potential for monthly injections with an average weight loss of 15.9% over 32 weeks, providing new hope for Pfizer in a competitive market.
- Increased Market Competition: With Pfizer entering the weight loss drug market, it will compete against giants like Novo Nordisk and Eli Lilly, which reported sales of $30 billion and $13.5 billion respectively, potentially undermining the pricing power of existing products.
- Diverse Clinical Trials: Pfizer is conducting multiple clinical trials for berobenatide, including 10 trials entering phase 3, indicating accelerated investment and strategic positioning in the weight loss drug sector.
- Long-Term Growth Potential: Pfizer anticipates a high single-digit revenue CAGR starting in 2029, although short-term performance may be impacted by declining COVID-19 drug sales, the potential of its weight loss drug business remains noteworthy.
See More
Eli Lilly Unveils Promising Data for New JAK2 Inhibitor in Myelofibrosis
- Clinical Trial Progress: Eli Lilly's AJX-101 study reveals promising safety and clinical activity for its novel type II JAK2 inhibitor AJ1-11095 in myelofibrosis patients who have failed type I JAK2 inhibitors, indicating significant therapeutic potential.
- Efficacy Metrics: Among 23 patients, 70% achieved a 35% reduction in spleen volume and the same percentage reported a 50% improvement in symptom burden at 12 weeks, suggesting the drug's efficacy surpasses existing treatments.
- Safety Assessment: The overall safety profile of AJ1-11095 is favorable, with no dose-limiting toxicities observed and 78% of patients remaining in the study during the dose escalation phase, indicating good tolerability and persistence.
- Future Research Directions: Lilly plans to further evaluate AJ1-11095 in high-risk polycythemia vera patients and those with myelofibrosis who have not yet received a JAK2 inhibitor, aiming to expand its clinical application and improve patient outcomes.
See More
Eli Lilly Unveils Promising Data for New JAK2 Inhibitor AJ1-11095
- Clinical Trial Progress: Eli Lilly's AJX-101 study evaluated the first-in-class type II JAK2 inhibitor AJ1-11095 in 23 patients with myelofibrosis previously treated with type I JAK2 inhibitors, demonstrating a promising safety profile and potential new treatment options for resistant patients.
- Significant Efficacy Metrics: The study found that 70% of patients achieved at least a 35% reduction in spleen volume (SVR35) and 70% experienced over 50% symptom improvement (TSS50) at week 12, indicating AJ1-11095's potential to enhance patient quality of life.
- Variant Frequency Reduction: Among the 23 patients, 21 showed a decrease in driver mutation variant allele frequency (VAF), with 59% of patients achieving a VAF reduction of 20% or more and 35% achieving a reduction of 50% or more at week 24, highlighting AJ1-11095's unique advantage in tumor progression suppression.
- Manageable Safety Profile: The overall safety of AJ1-11095 was manageable with no dose-limiting toxicities observed, and 78% of patients remain in the study, with common adverse events including anemia and dysgeusia, demonstrating the drug's feasibility in clinical applications.
See More
Future Outlook for Obesity Drugs Market
- Intensifying Market Competition: At the conference in New Orleans, Eli Lilly and Novo Nordisk showcased their GLP-1 drugs, with Novo's Wegovy prescriptions exceeding 3 million within five months of launch, indicating that oral medications are attracting more consumers and could reshape the weight loss drug market.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data, and if their GLP-1 drugs succeed in Phase 3 trials, they are expected to hit the market by 2029, further enriching market options and intensifying competition.
- Innovative Administration Methods: Pfizer's new drug shows potential for monthly administration, which could be more convenient than current weekly injections, while Amgen is testing a drug that could be administered monthly or quarterly, aiming to enhance patient adherence to treatment.
- Future Market Outlook: With approximately 2.5 billion people globally classified as overweight and 890 million as obese, the competition will intensify as new drugs continue to emerge, while Lilly and Novo are also working to improve insurance coverage for GLP-1 drugs, which is expected to attract more patients.
See More
Pfizer's New Drug Intensifies Competition in Weight Loss Market
- Pfizer's Drug Introduction: Pfizer's weight loss drug berobenatide, requiring only monthly injections, is set to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound, potentially putting market pressure on both companies.
- Clinical Trial Results: The latest phase 2b trial showed an average weight loss of 15.9%, and while Novo Nordisk and Eli Lilly's drugs may perform better under clinical management, the convenience of berobenatide could attract more patients.
- Market Outlook Analysis: Morgan Stanley projects the weight loss drug market will reach $150 billion by 2035, and Pfizer's entry may weaken the pricing power of Novo Nordisk and Eli Lilly, impacting their future revenues.
- Long-term Strategic Impact: Pfizer plans to launch multiple weight loss drugs in the coming years, and although the short-term revenue contribution may be limited, the enhanced competitiveness poses a potential threat to shareholders of Novo Nordisk and Eli Lilly.
See More
Analysis of Three Dividend Growth Stocks
- Eli Lilly's Strong Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase, with EPS soaring 156% to $8.55, driven by the success of its GLP-1 drug Mounjaro, and forecasts 2026 revenue between $82 billion and $85 billion, indicating robust market demand and future growth potential.
- Parker-Hannifin's Resilient Performance: Parker-Hannifin raised its dividend by 11% to $2 per share in April, marking its 70th consecutive year of increases, with a five-year dividend growth rate nearing 94%, while overall revenue grew 11% to $5.5 billion in Q3, showcasing its strong pricing power in global supply chains and clean technology infrastructure.
- Microsoft's Dual Growth in Revenue and Dividends: Microsoft reported Q3 revenue of $82.9 billion, an 18% year-over-year increase, with EPS rising 23% to $4.27, and a 10% dividend increase to $0.91 per quarter last September, reflecting its sustained growth in cloud computing and AI sectors.
- Investment Opportunities in Dividend Growth: These three companies have not only increased dividends by over 50% in the past five years but also maintain payout ratios below 27%, indicating their capacity for continued dividend increases, making them suitable for investors seeking stable income and capital appreciation.
See More
Pfizer Enters Weight Loss Drug Market with Berobenatide
- Drug Development Progress: Pfizer's weight loss drug berobenatide shows promise in its latest phase 2b trial, indicating potential for monthly injections with an average weight loss of 15.9% over 32 weeks, providing new hope for Pfizer in a competitive market.
- Increased Market Competition: With Pfizer entering the weight loss drug market, it will compete against giants like Novo Nordisk and Eli Lilly, which reported sales of $30 billion and $13.5 billion respectively, potentially undermining the pricing power of existing products.
- Diverse Clinical Trials: Pfizer is conducting multiple clinical trials for berobenatide, including 10 trials entering phase 3, indicating accelerated investment and strategic positioning in the weight loss drug sector.
- Long-Term Growth Potential: Pfizer anticipates a high single-digit revenue CAGR starting in 2029, although short-term performance may be impacted by declining COVID-19 drug sales, the potential of its weight loss drug business remains noteworthy.
See More
